
Protocol: ADA Bridging ELISA for Use with Anti-Nirsevimab (Beyfortus) Antibodies

Protocol: ADA Bridging ELISA for Use with Anti-Nirsevimab (Beyfortus) Antibodies
Download PDF
Anti-Drug Antibody (ADA) Bridging ELISA: For Use with Anti-Nirsevimab Monoclonal Antibodies Catalog HCA450, HCA451, HCA452
This method provides a procedure for generating an ADA ELISA standard curve with Anti-Nirsevimab Antibody, HCA450, HCA451, HCA452, using nirsevimab antibody for capture and detection. The method should always be used in conjunction with product and batch-specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.
View all nirsevimab (Beyfortus) antibodies
Reagents
- BSA (Sigma-Aldrich, A7906)
- HISPEC Assay Diluent (BUF049)
- Human Serum (Sigma-Aldrich, H4522)
- Phosphate buffered saline (PBS)
- 136 mM NaCl
2.68 mM KCl
8.1 mM Na2HPO4
1.46 mM KH2PO4
- PBST
- PBS with 0.05% Tween 20 (Merck Millipore, 817072)
- QuantaBlu Fluorogenic Peroxidase Substrate (Thermo Fisher Scientific, 15169)
LYNX Rapid Plus Biotin (Type 2) Antibody Conjugation Kit™ (e.g., LNK273B) or LYNX Rapid Plus Biotin (Type 1) Antibody Conjugation Kit (e.g., LNK263B)
Pierce High Sensitivity NeutrAvidin-HRP (Thermo Scientific, 31030)
Materials
- 384-well microtiter plate, black, square flat-bottom wells, for example, Black 384-Well Immuno Plates (Thermo Fisher Scientific, 460518)
- Fluorescence plate reader
96-well plates can be used instead of 384-well plates (black, flat-bottom wells), for example, Black 96-Well Immuno Plates (Thermo Fisher Scientific, 437111). For the 96-well format, use 100 μL (instead of 20 μL) of antigen, antibodies, or substrate and 300 μL for the blocking step.
Method
-
Prepare detection antibody: conjugate nirsevimab antibody using a LYNX Rapid Plus Biotin Antibody Conjugation Kit.
-
Prepare the unconjugated nirsevimab capture antibody at 1 µg/mL in PBS. Coat the required number of wells of a 384-well microtiter plate with 20 µL per well of the prepared nirsevimab, and incubate overnight at 4°C.
-
Wash the microtiter plate five times (5x) with PBST.
-
Block the microtiter plate by adding 100 µL 5% BSA in PBST to each well, and then incubate for 1 hr at RT.
-
Wash the microtiter plate 5x with PBST.
-
For the standard curve, prepare a dilution series of the Anti-Nirsevimab Antibody, HCA450, HCA451, HCA452, in 10% human serum in PBST in triplicate. Final concentration of anti-nirsevimab antibody should cover the range from 0.008 ng/mL to 32,000 ng/mL. Include a zero anti-nirsevimab antibody concentration as the background value.
-
Add 20 µL of anti-nirsevimab antibody dilution per well (in triplicate for each standard recommended) and incubate for 1 hr at RT.
-
Wash the microtiter plate 5x with PBST.
-
To each well add 20 µL biotinylated nirsevimab diluted to 2 µg/mL in HISPEC Assay Diluent and incubate for 1 hr at RT.
-
Wash the microtiter plate 5x with PBST.
-
To each well add 20 µL NeutrAvidin-HRP diluted to 0.125 µg/mL (1:8,000) in HISPEC Assay Diluent and incubate for 1 hr at RT.
-
Wash the microtiter plate 10x with PBST.
-
Add 20 µL QuantaBlu Fluorogenic Peroxidase Substrate to each well and measure the fluorescence after 30 min.